Executive Team


Troels Jordansen, Chief Executive Officer

Troels Jordansen started his career in healthcare with Leo Pharmaceutical Product and after 4 years with Johnson & Johnson Orthopaedics was one of the initial Genzyme Europe hires to focus on commercialising Carticel and Epicel in 1996. Over the last 20 years Troels has worked for 5 different cellular therapy companies including Dutch IsoTis NV, Australian Clinical Cell Culture Pty Ltd and British Azellon Ltd. where he was a co-founder. Troels roles have covered sales, marketing and general management and the last 15 years as Managing Director and/or Chairman for private and public listed companies. Troels has been part of award winning management teams raising over €150 million. Troels became Chairman of Glycostem in January 2014 and CEO in July 2016.

Jan Spanholtz

Jan Spanholtz PhD, Chief Scientific Officer

Dr. Jan Spanholtz initiated Glycostem's research in the start-up phase in 2007 and is currently Chief Scientific Officer (CSO) of Glycostem. Dr. Jan Spanholtz has more than 15 years of expertise in research on stem cell biology and immunology at universities and within biotech companies. He is author of various peer-reviewed research articles and inventor of Glycostem's proprietary technology platform to generate oNKord® from umbilical cord blood stem cells. For Glycostem, he has set-up and managed several national and international collaborations and spearheaded clinical translational of Glycostem's NK-cell product, oNKord®. He has developed the core IP strategy for Glycostem as inventor of feeder cell free NK-cell culture method from cord blood stem cells, synthetic culture medium for NK-cells and has was also part of several other patent applications in the stem cell field.

Volker Huppert

Volker Huppert Dipl.-Ing., Chief Operations Officer

Volker Huppert is a graduated bioprocess engineer from RWTH Aachen University. Volker has participated in set-up of quality system for a medical device/biotechnology company, and has developed several clinical level reagents, disposable tubing sets and process software for cell separation and cell culture medical devices. He contributed to tubing set and process software development of a leading cell therapy manufacturing device plus managed projects and teams for the development of cell manufacturing procedures for hematopoietic stem cells and Natural Killer cells. With 20 years’ experience in a leading biotechnology company Volker has published 12 papers in peer reviewed journals and is co-inventor of 9 patent families, including methods for T cell depletion of hematopoietic stem cell products, NK cell transduction and NK cell proliferation.

Hareth Nahi

Dr. Hareth Nahi MD, Chief Medical Officer

Hareth Nahi is a specialist in internal medicine and hematology, and has held the position of senior consultant in the Department of Hematology at the Karolinska University Hospital, Stockholm, Sweden since 2003. He is also Associate Professor in Hematology and Group Leader at the Center for Hematology and Regenerative Medicine (HERM) at the Dept of Medicine Huddinge, Karolinska Institutet since 2009, the research program focuses on cytogenetic and therapeutic mechanisms in multiple myeloma

Dr Nahi has been Chair of the Nordic Myeloma Study Group (NMSG) from November 2015 to present.  His other academic distinctions and merits include being a Member of the scientific committee at Black Swan Research initiative (BSRI).

Past appointments include Guest Editor for Lancet Oncology, Consultant for Cell Protect (cancer immunotherapy company) and Co-founder of Vycellix and Cell Protect. Dr Nahi is an author and co-author of more than 80 peer-reviewed publications and has participated in many clinical trials focusing on multiple myeloma but also involving patients with AML and lymphomas.

didier haguenauer

Dr Didier Haguenauer MD, ESSEC, Senior Vice President of Clinical Affairs

Prior to joining Glycostem in June 2018, Didier had an extensive experience of Clinical Research, Medical Affairs and Health Technology Assessment in the Pharma and Biotech industry for more than 25 years, including cell therapy in hematologic malignancies, small molecules and biomarkers in oncology.

His experience includes both clinical stage companies, and big Pharmas like AstraZeneca.

Jeroen Pieper

Jeroen Pieper PhD, Regulatory Advisor

Jeroen Pieper has over 15 years of experience in the life science and biomedical industry. Jeroen acquired his PhD in Medical and Life Science at the University Medical Centre Radboud in the Netherlands. Since then Jeroen has held senior scientist and project management position for IsoTis/Integra in the Netherlands and USA. Jeroen has published more than 20 papers in peer reviewed scientific journals. He joined Signifix as a RA/QA consultant in 2008 where he is currently employed as a Principal Regulatory Affairs Consultant.

Richard vd Linden

Richard van der Linden PhD, Quality Advisor

Richard van der Linden has more than 15 years experience in biotechnology ranging from research to production including quality management and regulatory affairs. He acquired his PhD in Molecular Immunology at University of Utrecht. Commercial experience was gained as senior scientist at Crucell NV and as Director Operations CatchMabs BV working with (therapeutic) antibodies. At CatchMabs BV Richard was responsible for production/quality management and introduced GMP. He joined Signifix in 2006 where he has gained ample experience in the tissue and cells, ATMPs and Medical Devices field. He currently holds the position as senior QA/RA consultant.

Marty Wulferink

Marty Wulferink PhD, IP Advisor

Marty Wulferink obtained his PhD at Utrecht University on the subject of chemical induced allergy and autoimmunity. After working as a postdoctoral fellow and later as project manager for a start-up pharmaceutical/biotech company for six years, Marty joined one of the largest patent firms of the Netherlands to become Dutch patent attorney and European patent attorney. Marty has a strong background in cell biology and immunology and obtained insight in clinical pharmaceutical development. He is co-inventor on 4 patent families and has published 15 papers in peer-reviewed journals. During and after his training to become patent attorney he gained hands-on working experience in the field of advising start-up companies and universities concerning biological and/or pharmaceutical inventions, diagnostic inventions, licensing, research agreements and Third Party Rights analyses.

Bianca Eve

Bianca Eve, HR Advisor

Bianca Eve has over 15 years experience in Human Resource Management. Besides a degree in HR Bianca has successfully followed Business Management and Corporate Anthropology. Bianca worked in different type of organizations amongst a general hospital and since 2011 she is self employed. The values logic, results and respect characterize her way of working.

Subscribe to our newsletter

If you subscribe you agree to the Privacy Notice of Glycostem Therapeutics B.V. as found on the website.